M2Bio Sciences Food and Beverage Launches CBD Sachets

CAPE TOWN, SA / ACCESSWIRE / July 21, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

M2Bio Sciences Food & Beverage is pleased to announce the launch of the M2Bio 10mg CBD Dissolvable Powder Sachets. The sachets are the latest innovation from the Company’s M2Bio brand portfolio of products, offering adults the opportunity to enjoy CBD their way. The sachet contains high-quality CBD isolate sourced from Oregon, USA. Each sachet contains 10mg of water-soluble CBD.

The convenient pre-packaged powder format makes it easy to mix the sachets contents into any beverage quickly and easily. The versatility of the product enables the consumer to enjoy premium CBD in a wide variety of settings and on any occasion of their choosing.

“The M2Bio CBD Sachets showcase the creativity, focus, and expertise of M2Bio’s product development team and reinforces our company commitment to growth through innovation. Consumers who have tried our Medspresso™ CBD beverage range also enquired about CBD in its raw form. Offering the customers, the water-soluble CBD powder, allows them the flexibility to infuse it with other foods and beverages as well. Ultimately, we want to get as many people to experience the health benefits of CBD and this is a step in the right direction. We have developed a process and product that blend science and individual tastes to help adults explore new, personal CBD experiences,” says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

Key features of the M2Bio CBD Sachets include the following:

  • Customizable: Can easily be added to almost any beverage, transforming it into a CBD-infused drink in a matter of seconds.
  • Rapid: M2Bio Sachets dissolve rapidly into beverages for a quick, straightforward CBD experience. In addition, the nano-emulsion formula provides improved absorption compared to traditional edibles and other delivery mechanisms.
  • Discreet: M2Bio Sachets are odorless and mixes in clear to most drinks, making it a discreet addition. It also contains no added flavor.
  • Co-branding opportunities: The nature of the product makes for a perfect co-branding opportunity with any beverage manufacturer, healthcare sector, retailers, hospitality, travel and tourism industries.

The sachets will be available to consumers in four formats:

  1. Single serve sachets – 10 mg CBD available at select retail outlets at POS.
  2. Pack of 5 sachets – 10 mg CBD x 5.
  3. Box of 60 Sachets – 10 mg CBD x 60. Monthly supply.
  4. Bulk Orders for B2B – 10 mg CBD x >2000 sachets.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™, and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)

Website: www.m2bio.co


Follow us on Twitter: https://twitter.com/m2bio

Follow us on Facebook: http://www.facebook.com/m2bio

Follow us on Instagram: https://www.instagram.com/m2bio.sciences

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.

View source version on accesswire.com: